NK cells preferentially target tumor cells with a cancer stem cell phenotype

Journal of Immunology

Volumn 195, Issue 8, 2015, Pages 4010-4019

  Ames, Erik ^a   Canter, Robert J ^a   Grossenbacher, Steven K ^a   Mac, Stephanie ^a   Chen, Mingyi ^a   Smith, Rachel C ^a   Hagino, Takeshi ^a   Perez Cunningham, Jessica ^a   Sckisel, Gail D ^a   Urayama, Shiro ^a   Monjazeb, Arta M ^a   Fragoso, Ruben C ^a   Sayers, Thomas J ^b   Murphy, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; DEATH RECEPTOR 5; FAS ANTIGEN; HERMES ANTIGEN; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GLIOMA; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; TUMOR VOLUME; UPREGULATION; ANIMAL; CELLULAR IMMUNITY; IMMUNOLOGY; NEOPLASM; NONOBESE DIABETIC MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84943543488     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500447     Document Type: Article

References (36)

1. Visvader, J. E., and G. J. Lindeman. 2012. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10:717-728.
2. Chen, J., Y. Li, T. S. Yu, R. M. McKay, D. K. Burns, S. G. Kernie, and L. F. Parada. 2012. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522-526.
3. Valent, P., D. Bonnet, R. De Maria, T. Lapidot, M. Copland, J. V. Melo, C. Chomienne, F. Ishikawa, J. J. Schuringa, G. Stassi, et al. 2012. Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer 12:767-775.
4. Driessens, G., B. Beck, A. Caauwe, B. D. Simons, and C. Blanpain. 2012. Defining the mode of tumour growth by clonal analysis. Nature 488:527-530.
5. Wang, L., P. Park, H. Zhang, F. La Marca, and C. Y. Lin. 2011. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int. J. Cancer 128:294-303.
6. Charafe-Jauffret, E., C. Ginestier, F. Bertucci, O. Cabaud, J. Wicinski, P. Finetti, E. Josselin, J. Adelaide, T. T. Nguyen, F. Monville, et al. 2013. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res. 73:7290-7300.
7. Charafe-Jauffret, E., C. Ginestier, F. Iovino, C. Tarpin, M. Diebel, B. Esterni, G. Houvenaeghel, J. M. Extra, F. Bertucci, J. Jacquemier, et al. 2010. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16:45-55.
8. Deng, S., X. Yang, H. Lassus, S. Liang, S. Kaur, Q. Ye, C. Li, L. P. Wang, K. F. Roby, S. Orsulic, et al. 2010. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1(ALDH1), in human epithelial cancers. PLoS One 5:e10277.
9. Douville, J., R. Beaulieu, and D. Balicki. 2009. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 18:17-25.
10. Ginestier, C., M. H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C. G. Kleer, S. Liu, et al. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567.
11. Hermann, P. C., S. L. Huber, T. Herrler, A. Aicher, J. W. Ellwart, M. Guba, C. J. Bruns, and C. Heeschen. 2007. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313-323.
12. Rasheed, Z., Q. Wang, and W. Matsui. 2010. Isolation of stem cells from human pancreatic cancer xenografts. J. Vis. Exp. (43):2169.
13. Rasheed, Z. A., J. Yang, Q. Wang, J. Kowalski, I. Freed, C. Murter, S. M. Hong, J. B. Koorstra, N. V. Rajeshkumar, X. He, et al. 2010. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl. Cancer Inst. 102:340-351.
14. Awad, O., J. T. Yustein, P. Shah, N. Gul, V. Katuri, A. O'Neill, Y. Kong, M. L. Brown, J. A. Toretsky, and D. M. Loeb. 2010. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 5:e13943.
15. Jiang, X., Y. Gwye, D. Russell, C. Cao, D. Douglas, L. Hung, H. Kovar, T. J. Triche, and E. R. Lawlor. 2010. CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 10:116.
16. Lohberger, B., B. Rinner, N. Stuendl, M. Absenger, B. Liegl-Atzwanger, S. M. Walzer, R. Windhager, and A. Leithner. 2012. Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PLoS One 7:e43664.
17. Canter, R. J., E. Ames, S. Mac, S. K. Grossenbacher, M. Chen, C. S. Li, D. Borys, R. C. Smith, J. Tellez, T. J. Sayers, et al. 2014. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer 14:756.
18. Penchev, V. R., Z. A. Rasheed, A. Maitra, and W. Matsui. 2012. Heterogeneity and targeting of pancreatic cancer stem cells. Clin. Cancer Res. 18:4277-4284.
19. Ames, E., and W. J. Murphy. 2014. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol. Immunother. 63:21-28.
20. Klingemann, H. G. 2013. Cellular therapy of cancer with natural killer cellswhere do we stand? Cytotherapy 15:1185-1194.
21. Barao, I., and W. J. Murphy. 2003. The immunobiology of natural killer cells and bone marrow allograft rejection. Biol. Blood Marrow Transplant. 9:727-741.
22. Liao, T., A. M. Kaufmann, X. Qian, V. Sangvatanakul, C. Chen, T. Kube, G. Zhang, and A. E. Albers. 2013. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J. Cancer Res. Clin. Oncol. 139:159-170.
23. Di Tomaso, T., S. Mazzoleni, E. Wang, G. Sovena, D. Clavenna, A. Franzin, P. Mortini, S. Ferrone, C. Doglioni, F. M. Marincola, et al. 2010. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16:800-813.
24. Berg, M., A. Lundqvist, P. McCoy, Jr., L. Samsel, Y. Fan, A. Tawab, and R. Childs. 2009. Clinical-grade ex vivo-expanded human natural killer cells upregulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11:341-355.
25. Ames, E., W. H. Hallett, and W. J. Murphy. 2009. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin. Exp. Immunol. 155:504-513.
26. Barao, I., M. Alvarez, D. Redelman, J. M. Weiss, J. R. Ortaldo, R. H. Wiltrout, and W. J. Murphy. 2011. Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation. Biol. Blood Marrow Transplant. 17:1754-1764.
27. Schepers, A. G., H. J. Snippert, D. E. Stange, M. Van Den Born, J. H. Van Es, M. Van De Wetering, and H. Clevers. 2012. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337:730-735.
28. Tseng, H. C., A. Arasteh, A. Paranjpe, A. Teruel, W. Yang, A. Behel, J. A. Alva, G. Walter, C. Head, T. O. Ishikawa, et al. 2010. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One 5:e11590.
29. Tallerico, R., M. Todaro, S. Di Franco, C. Maccalli, C. Garofalo, R. Sottile, C. Palmieri, L. Tirinato, P. N. Pangigadde, R. La Rocca, et al. 2013. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J. Immunol. 190:2381-2390.
30. Avril, T., E. Vauleon, A. Hamlat, S. Saikali, A. Etcheverry, C. Delmas, S. Diabira, J. Mosser, and V. Quillien. 2012. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol. 22:159-174.
31. Takashina, T., and M. Nakayama. 2007. Modifications enhance the apoptosisinducing activity of FADD. Mol. Cancer Ther. 6:1793-1803.
32. Holmström, T. H., S. E. Tran, V. L. Johnson, N. G. Ahn, S. C. Chow, and J. E. Eriksson. 1999. Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol. Cell. Biol. 19:5991-6002.
33. Gao, M. Q., Y. P. Choi, S. Kang, J. H. Youn, and N. H. Cho. 2010. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29:2672-2680.
34. Mistry, A. R., and C. A. O'Callaghan. 2007. Regulation of ligands for the activating receptor NKG2D. Immunology 121:439-447.
35. Jewett, A., Y. G. Man, and H. C. Tseng. 2013. Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J. Cancer 4:12-24.
36. Asai, O., D. L. Longo, Z. G. Tian, R. L. Hornung, D. D. Taub, F. W. Ruscetti, and W. J. Murphy. 1998. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J. Clin. Invest. 101:1835-1842.